Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/20384
Título
Systemic treatment of renal cell cancer: A comprehensive review
Autor(es)
Fecha de publicación
2017-11
Cita
Sanchez-Gastaldo A, Kempf E, Gonzalez Del Alba A, Duran I. Systemic treatment of renal cell cancer: A comprehensive review. Cancer Treat Rev. 2017 Nov;60:77-89. Epub 2017 Sep 1.
Idioma
Inglés
Tipo de documento
review article
Resumen
Kidney cancer represents about 5% of all new cancer diagnoses. The most common form of kidney cancer arises from renal epithelium, named renal cell carcinoma (RCC). This entity comprises different histological and molecular subtypes. Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients. This article reviews all the agents currently approved for the treatment of RCC, and discuss upcoming molecules. Mechanism of action, preclinical and clinical development and ongoing trials, are presented for each agent, providing a broad vision of the current state of targeted therapy in RCC and possible future developments.
Palabras clave
Renal cell cancer | Targeted therapy | Angiogenesis | Monoclonal antibody | Tyrosine-kinase inhibitor | mTOR inhibitor | Immunotherapy
MESH
Carcinoma, Renal Cell | Immunotherapy | Molecular Targeted Therapy | Kidney Neoplasms | Humans | Antineoplastic Agents
DECS
Antineoplásicos | Humanos | Inmunoterapia | Terapia Molecular Dirigida | Carcinoma de Células Renales | Neoplasias Renales
Versión en línea
DOI
Aparece en las colecciones
Acceso a texto completo